Goldman Scarlato & Karon, P.C. (“GSK”) commenced an investigation into the August 5, 2009 secondary offering of shares by STEC, Inc. (NASDAQ: STEC) (“STEC”) for $31.00 per share. The investigation is to determine whether STEC violated the federal securities laws by making false and misleading statements in documents filed with the U.S. Securities and Exchange Commission in connection with its August 5, 2009 secondary offering.

What You May Do

If you purchased STEC shares on August 5, 2009 or as part of the August 5, 2009 Offering and/or have information that would assist GSK in its investigation or would like to discuss your legal rights, you may, without obligation or cost to you, e-mail or call Mark S. Goldman, Esq. at (888) 668-4130 or send an email to Mr. Goldman at

About Goldman Scarlato & Karon, P.C.

GSK prosecutes securities fraud, consumer fraud, price-fixing, ERISA class actions, and shareholder-derivative litigation throughout the United States. The Firm’s lawyers have recovered hundreds of millions of dollars on behalf of consumers, investors, and businesses.

To learn more about Goldman Scarlato & Karon, P.C., please visit our website,

Copyright Business Wire 2010

If you liked this article you might like

5 Stocks Ready to Break Out

The Deal: Western Digital Rebounds Following sTec Acquisition

5 Breakout Stocks Ready to Surge Higher

Inefficiency, Dry Powder and Deep Value

5 Stocks Insiders Are Snapping Up